🚀 VC round data is live in beta, check it out!
BeOne Medicines Valuation Multiples
Discover revenue and EBITDA valuation multiples for BeOne Medicines and similar public comparables like Teva Pharmaceuticals, Sandoz, Otsuka Holdings, Insmed and more.
BeOne Medicines Overview
About BeOne Medicines
BeOne Medicines Ltd is a holding company. Through its subsidiaries, it operates as an oncology-focused biopharmaceutical company engaged in the discovery and development of treatments for cancer. Its portfolio includes BRUKINSA (a Bruton's tyrosine kinase (BTK) inhibitor), sonrotoclax (a B-cell lymphoma 2 (BCL2) inhibitor, and a BTK chimeric degradation activation compound (BTK-CDAC). The company develops and commercializes wholly owned therapeutic assets targeting multiple mechanisms of action in oncology. The company operates in one segment: pharmaceutical products. It generates the majority of its revenue from the sale of its biopharmaceutical products.
Founded
2010
HQ
Employees
12.0K
Website
Sectors
Financials (LTM)
EV
$33B
BeOne Medicines Financials
BeOne Medicines reported last 12-month revenue of $6B and EBITDA of $716M.
In the same LTM period, BeOne Medicines generated $5B in gross profit, $716M in EBITDA, and $381M in net income.
Revenue (LTM)
BeOne Medicines P&L
In the most recent fiscal year, BeOne Medicines reported revenue of $5B and EBITDA of $617M.
BeOne Medicines expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $6B | XXX | $5B | XXX | XXX | XXX |
| Gross Profit | $5B | XXX | $5B | XXX | XXX | XXX |
| Gross Margin | 88% | XXX | 87% | XXX | XXX | XXX |
| EBITDA | $716M | XXX | $617M | XXX | XXX | XXX |
| EBITDA Margin | 13% | XXX | 12% | XXX | XXX | XXX |
| EBIT Margin | 9% | XXX | 8% | XXX | XXX | XXX |
| Net Profit | $381M | XXX | $287M | XXX | XXX | XXX |
| Net Margin | 7% | XXX | 5% | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
BeOne Medicines Stock Performance
BeOne Medicines has current market cap of $36B, and enterprise value of $33B.
Market Cap Evolution
BeOne Medicines' stock price is $25.07.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $33B | $36B | 0.7% | XXX | XXX | XXX | $0.20 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialBeOne Medicines Valuation Multiples
BeOne Medicines trades at 5.8x EV/Revenue multiple, and 45.7x EV/EBITDA.
EV / Revenue (LTM)
BeOne Medicines Financial Valuation Multiples
As of April 11, 2026, BeOne Medicines has market cap of $36B and EV of $33B.
Equity research analysts estimate BeOne Medicines' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
BeOne Medicines has a P/E ratio of 95.0x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $36B | XXX | $36B | XXX | XXX | XXX |
| EV (current) | $33B | XXX | $33B | XXX | XXX | XXX |
| EV/Revenue | 5.8x | XXX | 6.1x | XXX | XXX | XXX |
| EV/EBITDA | 45.7x | XXX | 53.0x | XXX | XXX | XXX |
| EV/EBIT | 61.8x | XXX | 73.2x | XXX | XXX | XXX |
| EV/Gross Profit | 6.6x | XXX | 7.0x | XXX | XXX | XXX |
| P/E | 95.0x | XXX | 126.1x | XXX | XXX | XXX |
| EV/FCF | 48.1x | XXX | 38.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified BeOne Medicines Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
BeOne Medicines Margins & Growth Rates
BeOne Medicines' revenue in the last 12 month grew by 19%.
BeOne Medicines' revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $0.4M for the same period.
BeOne Medicines' rule of 40 is 35% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
BeOne Medicines' rule of X is 65% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
BeOne Medicines Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 19% | XXX | 20% | XXX | XXX | XXX |
| EBITDA Margin | 13% | XXX | 12% | XXX | XXX | XXX |
| EBITDA Growth | 58% | XXX | 61% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 35% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 65% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.4M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.4M | XXX | XXX | XXX |
| S&M Expenses to Revenue | 30% | XXX | 31% | XXX | XXX | XXX |
| G&A Expenses to Revenue | 13% | XXX | 13% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 40% | XXX | 40% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 79% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
BeOne Medicines Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Teva Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| Sandoz | XXX | XXX | XXX | XXX | XXX | XXX |
| Otsuka Holdings | XXX | XXX | XXX | XXX | XXX | XXX |
| Insmed | XXX | XXX | XXX | XXX | XXX | XXX |
| Daiichi Sankyo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
BeOne Medicines M&A Activity
BeOne Medicines acquired XXX companies to date.
Last acquisition by BeOne Medicines was on XXXXXXXX, XXXXX. BeOne Medicines acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by BeOne Medicines
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialBeOne Medicines Investment Activity
BeOne Medicines invested in XXX companies to date.
BeOne Medicines made its latest investment on XXXXXXXX, XXXXX. BeOne Medicines invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by BeOne Medicines
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout BeOne Medicines
| When was BeOne Medicines founded? | BeOne Medicines was founded in 2010. |
| Where is BeOne Medicines headquartered? | BeOne Medicines is headquartered in United States. |
| How many employees does BeOne Medicines have? | As of today, BeOne Medicines has over 12K employees. |
| Who is the CEO of BeOne Medicines? | BeOne Medicines' CEO is John V. Oyler. |
| Is BeOne Medicines publicly listed? | Yes, BeOne Medicines is a public company listed on HKEX. |
| What is the stock symbol of BeOne Medicines? | BeOne Medicines trades under 06160 ticker. |
| When did BeOne Medicines go public? | BeOne Medicines went public in 2018. |
| Who are competitors of BeOne Medicines? | BeOne Medicines main competitors are Teva Pharmaceuticals, Sandoz, Otsuka Holdings, Insmed. |
| What is the current market cap of BeOne Medicines? | BeOne Medicines' current market cap is $36B. |
| What is the current revenue of BeOne Medicines? | BeOne Medicines' last 12 months revenue is $6B. |
| What is the current revenue growth of BeOne Medicines? | BeOne Medicines revenue growth (NTM/LTM) is 19%. |
| What is the current EV/Revenue multiple of BeOne Medicines? | Current revenue multiple of BeOne Medicines is 5.8x. |
| Is BeOne Medicines profitable? | Yes, BeOne Medicines is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of BeOne Medicines? | BeOne Medicines' last 12 months EBITDA is $716M. |
| What is BeOne Medicines' EBITDA margin? | BeOne Medicines' last 12 months EBITDA margin is 13%. |
| What is the current EV/EBITDA multiple of BeOne Medicines? | Current EBITDA multiple of BeOne Medicines is 45.7x. |
| What is the current FCF of BeOne Medicines? | BeOne Medicines' last 12 months FCF is $680M. |
| What is BeOne Medicines' FCF margin? | BeOne Medicines' last 12 months FCF margin is 12%. |
| What is the current EV/FCF multiple of BeOne Medicines? | Current FCF multiple of BeOne Medicines is 48.1x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.